Kiora Pharmaceuticals, Inc.
KPRX
$2.84
$0.1917.21%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | 0.00 | -- | -- |
Total Other Revenue | -- | -- | 0.00 | -- | 20.00K |
Total Revenue | -- | -- | 0.00 | -- | 20.00K |
Cost of Revenue | 96.10K | 2.53M | -3.34M | 1.32M | 94.10K |
Gross Profit | -96.10K | -2.53M | 3.34M | -1.32M | -74.10K |
SG&A Expenses | 1.35M | 1.49M | 1.33M | 1.38M | 1.54M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 2.26M | 2.06M | 2.51M | 2.70M | 2.44M |
Operating Income | -2.26M | -2.06M | -2.51M | -2.70M | -2.42M |
Income Before Tax | -2.26M | -2.07M | -2.16M | -3.41M | -2.22M |
Income Tax Expenses | -112.10K | 123.00K | 2.07M | -- | -- |
Earnings from Continuing Operations | -2.15M | -2.19M | -4.22M | -3.41M | -2.22M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -2.15M | -2.19M | -4.22M | -3.41M | -2.22M |
EBIT | -2.26M | -2.06M | -2.51M | -2.70M | -2.42M |
EBITDA | -2.26M | -2.05M | -2.50M | -2.70M | -2.42M |
EPS Basic | -0.54 | -0.52 | -1.00 | -0.81 | -0.53 |
Normalized Basic EPS | -0.33 | -0.27 | -0.30 | -0.37 | -0.31 |
EPS Diluted | -0.54 | -0.52 | -1.00 | -0.81 | -0.53 |
Normalized Diluted EPS | -0.33 | -0.27 | -0.30 | -0.37 | -0.31 |
Average Basic Shares Outstanding | 3.99M | 4.22M | 4.22M | 4.22M | 4.17M |
Average Diluted Shares Outstanding | 3.99M | 4.22M | 4.22M | 4.22M | 4.17M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |